𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Malignant lymphomas of the upper gastrointestinal tract. Results of a prospective study in 103 patients

✍ Scribed by Wolfgang Fischbach; Walter Kestel; Thomas Kirchner; Joachim Mössner; Klaus Wilms


Publisher
John Wiley and Sons
Year
1992
Tongue
English
Weight
560 KB
Volume
70
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.


📜 SIMILAR VOLUMES


Endoscopic palliation of malignancies of
✍ Pasquale Spinelli; Marco Dal Fante; Andrea Mancini 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 557 KB

Three hundred eight patients with obstructing malignant tumors of the gastrointestinal tract were submitted to endoscopic Nd:YAG laser palliation. The number of sessions as well as the number of days and total energy required for initial recanalization of the stenosis were related to tumor length. L

Multifocal aggressive lymphoma of the ga
✍ Carlos J. Castro; Paul Klimo; Anne Worth 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 353 KB 👁 2 views

This is a case report of an aggressive multifocal non-Hodgkin's lymphoma in a cadaver kidney recipient arising in the early phase of her immunosuppressive maintenance therapy program with cyclosporin A and prednisone.

Delay in the diagnosis of cutaneous mali
✍ Dr. J. E. J. Krige; S. Isaacs; D. A. Hudson; Helen S. King; R. M. Strover; Carol 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 511 KB

The extent and consequence of patient and professional delay in the diagnosis and treatment of 250 consecutive patients with primary cutaneous malignant melanoma was investigated. Mean total delay from the onset of observed change in a melanoma to appropriate therapy was 11.1 months. The major compo

Results of a pilot study of the effects
✍ Victor Lai; Jonathan George; Luther Richey; Hong J. Kim; Trinitia Cannon; Carol 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 144 KB 👁 2 views

## Abstract ## Background. Animal models suggest that cyclooxygenase‐2 (COX‐2) inhibitors may be beneficial in suppressing cancer cachexia. We investigated the effect of short‐course celecoxib on body composition, inflammation, and quality of life (QOL) in patients with cancer cachexia in a phase